In breast cancer, targeting CXCL7 inhibits tumor growth and metastasis [10], while in cholangiocarcinoma, CXCL7 promotes tumor proliferation and invasion via the AKT signaling pathway [22]. Here, AKT1 is linked to breast carcinoma.